Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.

Trial Details

NCT ID
NCT05978193
Phase
PHASE2
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • LDRT+CFRT
  • Immunotherapy
  • Chemotherapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Metastatic esophageal squamous cell carcinoma (stage IVB, M1) confirmed by pathology;
  • ECOG performance status: 0-1 point;
  • No prior anti-tumor treatment;
  • Adequate hematologic, renal, hepatic, and cardiac functions that meet the requirements for chemotherapy and immunotherapy assessed by investigators.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →